UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE: INSULIN PRICING LITIGATION

CASE NO. 2:23-MD-03080 MDL NO. 3080

DECLARATION OF BENJAMIN HAZELWOOD IN SUPPORT OF MOTION TO SEAL

THIS DOCUMENT RELATES TO:

County of Albany, New York v. Eli Lilly, et al., No. 1:22-cv-00981 King County v. Eli Lilly et al., No. 2:23-cv-21178 Lake County, Illinois v. Eli Lilly, et al., No. 2:23-cv-08487

- I, Benjamin Hazelwood, hereby declare pursuant to 28 U.S.C. § 1746 as follows:
- 1. I am over 21 years old, of sound mind, and under no legal disability. I have personal knowledge of the facts set forth in this Declaration and if called to testify in person about those facts, could and would do so competently under oath.
- 2. I am a member of the bars of the District of Columbia, New York, and Virginia and I am admitted *pro hac vice* to practice in this matter before this Court. I am a partner at the law firm Williams & Connolly LLP and represent Defendants CVS Health Corporation, CVS Pharmacy, Inc., Caremark Rx, L.L.C., Caremark PCS

Health, L.L.C., and Caremark, L.L.C (collectively, "CVS") in this action. As such, I am familiar with the facts and circumstances in this matter.

- 3. I submit this declaration in support of PBM Defendants' Motion to Seal Confidential Information contained in the following documents, which have been filed provisionally under seal:
- a. PBM Defendants' Memorandum in Support of Motion to Dismiss the Self-Funded Payor Track Complaints (Albany, King, and Lake Counties), filed August 22, 2024 ("PBM Defendants' Motion to Dismiss") [ECF No. 252];
- b. Exhibits 1-7 in Support of PBM Defendants' Motion to Dismiss, filed August 22, 2024 [ECF Nos. 253-1, 254-1 through 254-5, and 255-1];
- c. Self-Funded Payor Plaintiffs' Response in Opposition to PBM Defendants' Motion to Dismiss, filed August 22, 2024 [ECF No. 257]; and
- d. PBM Defendants' Reply in Support of PBM Defendants' Motion to Dismiss, filed August 22, 2024 [ECF No. 259].
- 4. Plaintiffs do not object to this request. I am aware of no party or non-party that objects to this request.
- 5. An Index, substantially in the form suggested by Appendix U to the Local Civil Rules, has been prepared identifying the proprietary and confidential information the PBM Defendants seek to seal (referred to herein as the "Confidential").

Materials"), including: (a) the nature of the materials or proceedings at issue; (b) the legitimate private or public interest which warrants the relief sought; (c) the clearly defined and serious injury that would result if the relief sought is not granted; (d) why a less restrictive alternative to the relief sought is not available; and (e) the identity of any party or nonparty known to be objecting to the sealing request. No prior order has been entered in this action sealing the same materials.

- 6. Attached to this Declaration as Exhibit 1 is a true and correct copy of the Index in Support of the PBM Defendants' Motion to Seal.
- 7. Attached to this Declaration as Exhibit 2 is a true and correct copy of the Declaration of Michael Perry, submitted on behalf of the CVS Defendants.
- 8. Attached to this Declaration as Exhibit 3 is a true and correct copy of the Declaration of Jim Engler, submitted on behalf of the ESI Defendants.
- 9. Attached to this Declaration as Exhibit 4 is a true and correct copy of the Declaration of David Liou, submitted on behalf of the OptumRx Defendants.
- 10. Additionally, redacted versions of the documents containing only portions of Confidential Materials—*i.e.*, those not sought to be maintained entirely under seal—are attached hereto as Exhibits 5, 6, 7.
- 11. Certain materials related to the Self-Funded Payor Track Motion to Dismiss briefing that were filed provisionally under seal on August 22, 2024—specifically, ECF Nos. 250, 250-1 through 250-23, 256, and 258—are expected to

be filed publicly on the docket with no redactions forthwith by the Manufacturer Defendants.

I declare under penalty of perjury that the foregoing statements are true and correct to the best of my knowledge.

Executed this 27th day of September, 2024, in Washington, DC.

/s/ Benjamin Hazelwood
Benjamin Hazelwood